Background Identification of variable epidermal growth factor receptor (EGFR) gene
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …

Highlights•Comprehensive review of EGFRTK inhibitors.•Helps in understanding the
structural and developmental aspects of small molecular EGFR TKIs.•Focuses on mutant …

Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …

Introduction Epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
and mutated in multiple cancers. In normal cell physiology, EGFR signaling controls cellular …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

Cancer is caused by a series of alterations in genome and epigenome mostly resulting in
activation of oncogenes or inactivation of cancer suppressor genes. Genetic engineering …

Dacomitinib (Vizimpro®) is an orally administered, small-molecule irreversible inhibitor of
HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid …

Lung cancer is the second most common malignant tumor and the leading cause of cancer
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …

Lung cancer is a serious health problem and the leading cause of cancer death worldwide,
due to its high incidence and mortality. 85% of lung cancers are represented by the non …

Lung cancer continues to be the most common cause of cancer-related mortality worldwide.
Recent advances in molecular diagnostics and immunotherapeutics have propelled the …